Summary
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. on February 11, 2016, primarily announces the company's financial results for the fourth quarter and full year ended December 31, 2015. While the 8-K itself is brief, it directs investors to a furnished press release (Exhibit 99.1) for the detailed financial performance and operational updates for the period. Investors should refer to the press release for specifics on revenue, net income/loss, cash position, and any forward-looking statements or pipeline updates. This filing serves as the formal notification of the release of this crucial financial information, marking a key reporting event for the company.
Key Highlights
- 1Announcement of Q4 and Full Year 2015 Financial Results.
- 2Financial results press release furnished as Exhibit 99.1.
- 3Filing date: February 11, 2016.
- 4Report covers the period ending December 31, 2015.
- 5Information furnished is not deemed 'filed' for Section 18 liability.
- 6The 8-K itself does not contain detailed financial figures, referencing the press release instead.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially announce Alnylam Pharmaceuticals, Inc.'s financial results for the fourth quarter and the full year ended December 31, 2015. It serves as a notification that a press release containing these details has been issued.
The detailed financial results and operational updates are provided in the press release dated February 11, 2016, which is furnished as Exhibit 99.1 to this Form 8-K filing. Investors should consult this exhibit for comprehensive information.
No, the Form 8-K itself does not contain the specific financial figures. It directs investors to the accompanying press release (Exhibit 99.1) for the detailed financial results, including revenue, net loss, and other key performance indicators for the period ending December 31, 2015.
The distinction means that while the information is publicly disclosed through the SEC filing, it is not subject to the strict liability provisions of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated into other SEC filings (like registration statements) unless specifically referenced. This is standard practice for press releases containing financial results.